Please use this identifier to cite or link to this item:
|Title:||Effect of combination of thalidomide and sulfasalazine in experimentally induced inflammatory bowel disease in rats|
|Keywords:||Inflammatory bowel disease|
Tumor necrosis factor-<img src='/image/spc_char/alpha.gif' border=0>
|Abstract:||Thalidomide provided significant protection against tri nitro benzene sulfonic acid induced colitis. Combination therapy also reduced colonic inflammation and all the biochemical parameters (myeloperoxidase assay, malondialdehyde assay and tumor necrosis factor-<img src='/image/spc_char/alpha.gif' border=0> , estimation) were significant as compared to control as well as thalidomide alone treated group. Combination therapy showed additive effect of thalidomide which restored lipid peroxidation as well as reduced myeloperoxidase and TNF-<img src='/image/spc_char/alpha.gif' border=0> towards the normal levels. Morphological and histological scores were significantly reduced in combination groups. In experimental model of colitis, oral administration of thalidomide (150 mg/kg) alone as well as its combination with sulfasalazine (360 mg/kg) significantly reduced the colonic inflammation. The results indicate the additive effect of thalidomide with sulfasalazine in rat colitis model which requires further confirmation in human studies.|
|ISSN:||0975-1009 (Online); 0019-5189 (Print)|
|Appears in Collections:||IJEB Vol.49(09) [September 2011]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.